
- Telehealth Visits
- Insurance plan information

Alfred Chung, MD
Hematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information



Alfred Chung, MD
Hematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Alfred Chung is a hematologist-oncologist who cares for patients with blood cancers, including leukemias, lymphomas and myelomas. He sees patients who are in the hospital for treatment, including those who need a bone marrow transplant and those receiving chemotherapy or cellular therapies to bolster the immune system.
Chung's research centers on the study and development of new therapies for plasma cell disorders, including multiple myeloma and amyloidosis (buildup of an abnormal protein called amyloid in the organs). One specific area of study is light chain amyloidosis, in which the dysfunction of certain antibody-producing cells results in abnormal protein fibers in the organs. Chung is looking specifically at targeted therapies to treat this type of amyloidosis as well as novel therapeutic strategies in the treatment of multiple myeloma.
After earning a bachelor's degree in chemical engineering at the University of Michigan, Chung earned a medical degree at Northwestern University Feinberg School of Medicine. At Stanford Medicine, he completed a residency in internal medicine, followed by a fellowship in hematology and oncology.
Chung is a member of the American Society of Clinical Oncology, American Society of Hematology and Association of Northern California Oncologists.
Education & training
Board certification
- Hematology, American Board of Internal Medicine/Hematology
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, Stanford University Hematology Fellowship Program
Residency
- Internal Medicine, Stanford Hospital and Clinics
Degree
- MD, Northwestern University Feinberg School of Medicine
My expertise
Specialties
- Hematology Oncology
- Myeloma
- Leukemia
- Lymphoma
Conditions
- Multiple Myeloma
- Light Chain (AL) Amyloidosis
- Leukemia
- Amyloidosis
Locations
My research
Clinical trials
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaOpens in a new window
Recruiting
Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory…A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsOpens in a new window
Recruiting
Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed…Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaOpens in a new window
Recruiting
Safety will be evaluated for the population of participants who received at least one dose of study drug. Treatment-emergent AEs will be graded by the Common…
Publications
Showing 1-6 of 66 reviews
- February 21, 20265 out of 5 Stars
Great doctor
- February 4, 20265 out of 5 Stars
I first spoke with a fellow who was very knowledgeable and took time to interact with me. My doctor joined us and again, he is very good to talk to, I feel comfortable and am confident in his recommendations for my treatment.
- January 9, 20265 out of 5 Stars
Dr. Chung provides excellent care to his patients.
- January 8, 20265 out of 5 Stars
My Dr. Communicates great for me!
- January 6, 20265 out of 5 Stars
An Awesome UCSF team!
- January 6, 20265 out of 5 Stars
I have been treated very well by all the UCSF staff
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.